UPDATE: OncoACP3‑DOTA, First‑in‑Human Therapeutic Signal Beyond PSMA

OncoACP3‑DOTA is a small‑molecule ligand directed at prostatic acid phosphatase (ACP3, also historically called PAP), a membrane‑bound phosphatase that is highly specific to the prostate, with only weak expression in normal tissues such as kidney. Preclinical work showed that ACP3 is retained in many prostate tumors, including lesions with low or absent PSMA expression, and […]

Complete Response to Pembrolizumab in a Metastatic, Castration‑Resistant Prostate Cancer Survivor

A remarkable case published in Annals of Internal Medicine: Clinical Cases highlights a man with metastatic, castration‑resistant prostate cancer who achieved a complete and durable response to pembrolizumab after exhausting multiple standard therapies. The patient had previously received abiraterone‑based treatment followed by chemotherapy, and then olaparib, all of which he had progressed on, leaving him […]